PLASMA CELL LEUKEMIA
Clinical trials for PLASMA CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for PLASMA CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug may reduce dangerous side effects of stem cell transplants in older patients
Disease control OngoingThis early-phase study tests whether the drug itacitinib can prevent a serious complication called cytokine release syndrome (CRS) after a stem cell transplant in people aged 60 and older with blood cancers. The study involves 32 participants who receive a 'mini' transplant from …
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
Multiple myeloma drug study canceled before starting
Knowledge-focused TerminatedThis study was designed to find the safest dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not responded to earlier treatments. It was a Phase 1 trial, meaning it was the first step in testing the drug in humans. However, the study was withdra…
Matched conditions: PLASMA CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated May 26, 2026 08:12 UTC
-
Lab tests aim to match myeloma patients with best drugs
Knowledge-focused OngoingThis pilot study explores whether using a lab test that screens many drugs at once, combined with genetic information, can help choose personalized treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to therapy. The goal is …
Matched conditions: PLASMA CELL LEUKEMIA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 20, 2026 11:53 UTC